Our findings taken together with clinical evidence that IGFBP3 promoter polymorphism contributes to prostate cancer risk [54, 55], and its potential biomarker value in prostate cancer patients [56], support the clinical significance of IGFBP3. Here, IGFBP3 is linked to prostate carcinoma.